Pfizer-BioNTech: Vaccine 5-11 Years Positive Phase 2/3 Results
Pfizer and BioNTech have announced the results of a study related to the anti-covid vaccine on children aged 5-11 years. The US pharmaceutical company and the German group announced that phase 2/3 “shows a favorable safety profile and a solid neutralizing antibody response in children between the ages of 5 and 11”, using a two-dose regimen of 10 micrograms. given 21 days apart, a dose lower than the 30 microgram dose used for people aged 12 years and over. “The antibody responses in participants who were given doses of 10 micrograms are comparable to those recorded in a previous Pfizer-BioNTech study in people aged 16 to 25 who were immunized with doses of 30 micrograms,” the note noted.
“We look forward to extending the vaccine protection to the younger population, especially as we follow the spread of the Delta variant and the substantial threat it poses to children,” said Albert Bourla, Pfizer president and chief executive officer. “Since July, pediatric cases of Covid-19 have increased by about 240% in the United States – he added -. These trial results provide a solid basis for requesting authorization of our vaccine for children aged 5 to 11. , and we plan to urgently submit them to the FDA and other regulators. “